Quarterly Earnings Report ~~July~~Octubre 28, 2014 ~~2Q12~~3Q14 Distribution Sales to Institutional Clients Declined while Chile and Mexico Demonstrated Improved Performance Financial Highlights: (All figures are expressed in millions of Mexican pesos. Comparisons are made with the same period of 2011, unless otherwise stated. Figures may vary slightly due to rounding). The Groups net sales for the fourth quarter reached $71,~~330~~168.309 million pesos Gross income for the period was $~~1,464~~556.78 million; the gross margin for the quarter was 1947.9867% Operating expenses reached $1,~~542~~185.89 million pesos and represented 21101.0552% of the Companys total sales. oSecond ~~Quarterly~~quarter ~~operating~~EBITDA ~~income~~ was of $-78605.05 million, ~~resulting~~or in-51.84% anof ~~operating~~total ~~margin~~sales ofOn ~~-1.07%~~Agust ~~for~~11 the ~~period.~~sale ~~Second~~of ~~quarter~~stake ~~EBITDA~~in ~~was~~Farmarcias ~~$-5~~Ahumada, S.4A. ~~million~~(FASA) to Alliance Boots Chile, oran ~~-0.07%~~Alliance ofBoots ~~total~~Chile, ~~sales~~BMbb Assubdiary, ofwas ~~June~~successfully completed. Up to september 30, 2014, ~~GCSs~~the group s net debt ~~totaled~~has ~~$7,082.8~~been ~~million~~fully opaid ~~GCS~~with ~~closed~~ the ~~quarter~~earning ~~with~~received 22for ~~Distribution~~our ~~Centers~~Famarcias Ahumada and ~~1,282~~subsidiaries ~~pharmacies~~division insale. ~~operation across Latin America~~ Mexico City, Mexico, ~~July~~September 2830, 2014. Grupo Casa Saba (SAB) (“Saba”, “GCS”, “the Company” or “the Group”), one of the leading Mexican distributors of pharmaceutical products as well as health, beauty aids and consumer goods and publication, and one of the most important pharmacy chains in Latin America, announces its consolidated financial and operating results for the second quarter of 2014. QUARTERLY EARNINGS InThe ~~the~~Farmacias ~~second~~Ahumada ~~quarter~~division ofand ~~2014~~its subsidiaries, ~~Saba~~with ~~faced~~presence ~~close competition~~ in ~~the~~Mexico ~~distribution~~ and ~~marketing~~Chile, ofwas ~~pharmaceutical~~sold ~~products,~~to ~~health~~Alliance ~~and~~Boots ~~beauty~~Chile ~~aids~~SpA, ~~and~~an ~~consumer~~Alliance ~~goods~~Boots insubsidiary ~~Mexico~~GmbH, asin ~~well~~August as2014 infor ~~the~~approximately ~~other~~$8,100 ~~Latin~~million ~~America~~pesos ~~countries~~ in ~~which~~effort weto ~~operate.~~settle ~~Our~~the ~~operating~~bank ~~strategy~~liabilities ~~maintained~~and ~~emphasis~~try onto ~~improving~~consolidate ~~efficiency~~the ~~levels~~distribution ~~and~~segment ~~controlling~~in ~~logistic~~Mexico. ~~costs~~Referring ~~and~~to ~~expenses,~~Mexico`s ~~generating~~distribution ~~positive~~segment, ~~results~~ in ~~practically~~the ~~all~~third ~~our~~quarter ~~divisions.~~of At2014 the ~~sales~~competition ~~level,~~in ~~we focused on improving~~ the ~~availability~~commercialization of the ~~most~~pharm, inhealth, ~~demand~~beauty ~~products~~and ~~for~~consumer ~~our~~goods ~~clients~~has inbeen ~~wholesale~~growing ~~and~~ in ~~our pharma network, as well as improving~~ the ~~care~~past ~~and~~years ~~service~~due ~~of our stock sales. In regards~~ to ~~growth,~~a ~~opening~~mayor ~~new~~number ~~pharmacies~~of participants in ~~Latin~~the ~~America~~markets ~~and~~that inwe ~~Mexico~~operate. ~~allowed~~Our usoperating tostrategy ~~strengthen~~emphasizes ~~our~~on ~~presence~~improving inlevels ~~the~~of ~~markets~~logistics inefficiency, ~~which~~controlling wecosts ~~already~~and ~~operate~~expenses, as well as tooffering ~~improve~~competitive ~~the~~prices ~~knowledge~~to ofgenerate ~~the~~positive ~~brands with which we operate~~results. ~~At Grupo Casa Saba~~Likewise, we ~~will~~remain ~~continue~~focused ~~to focus~~ on ~~making~~improving ~~ongoing~~the ~~improvements~~availability ~~to our logistic and commercial operations in order to offer all~~ of ~~our~~the ~~clients a wide range of~~ products atthat ~~competitive prices. In~~ our ~~pharmacy~~clients ~~network,~~demand ~~we will also strive~~ to ~~offer~~continue ~~the~~improving ~~best~~our ~~integrated~~attention ~~health, beauty~~ and ~~consumer goods solutions~~service. NET SALES Net sales for the quarter ~~reached~~totaled $71,~~330~~168.309 million, ana decrease of 3289.402% compared to $10,~~843~~635.305 million in ~~2Q2013~~3Q2013. ~~This~~Vs ~~increase resulted from~~ the ~~higher~~$1,168.09 ~~performance~~million in ~~our distribution division~~3Q2014. SALES BY DIVISON DISTRIBUTION DIVISION PHARMA, HEALTH, BEAUTY AND CONSUMER GOODS Sales from our Pharma, Health, Beauty and Consumer ~~Goods~~for ~~division~~the ~~increased~~third ~~3.46%~~quarter ~~versus~~of ~~the~~2014 ~~2Q2011,~~totalized ~~totaling~~ $1,~~704.6~~137 million. Compared towith the same quarter last year, athere ~~67.6%,~~was a decrease ~~was~~of ~~resulted~~89.19% mainly due to the disincorporation process of ~~Citem~~the ~~publication~~distribution division and its liquidity problems. In ~~terms~~addition ofto ~~total~~the ~~sales~~above, ~~this~~sales were negatively impact due to lower economic growth in the country during the 3rd quarter of 2014. Participation of total division’s ~~percentage~~sales ~~went~~decreased from 4898.692% in ~~2Q2013~~the 3T2013 to 2397.334% in the ~~2Q2014~~3T2014. GOVERNMENTPHARMA Quarterly sales in our Government Pharma division totalized $~~66.3~~31 ~~millon~~million. This division registered a 2472.995% ~~increase~~decrease in sales compared to the ~~second~~third quarter of 2013, product of a deferral on the date of tenders. In terms of total sales, this division passed from 01.508% in 2Q2013 to 02.966% in the ~~2Q2014~~3Q2014. RETAIL PHARMACY ~~During~~The ~~the~~Pharmacy ~~second~~division ~~quarter~~was ofsold ~~the~~to ~~year,~~a ~~sales~~third ~~from~~party ~~our~~in ~~Retail~~this ~~Pharmacy~~quarter; ~~division~~therefore, ~~reached~~there ~~$5,559.3~~were ~~million.~~no ~~Compared~~sales toin the ~~same~~third quarter ~~last year, the increase was~~ of 02014.~~7%.~~ ~~The~~During ~~increase was mainly due to~~ the ~~correct~~third ~~implementation~~quarter of ~~our~~2013, ~~growth~~sales ~~strategy~~from ~~implemented~~our inRetail ~~the~~Pharmacy ~~markets~~division inreached ~~which~~$5,540.5 ~~we operate~~million. This divisions percentage of the Groups overall sales rose to 7552.866% ~~vs 50.9%~~ in the ~~2Q2013~~3Q2013. As a result, the sales mix ~~for~~up ~~the~~to ~~second~~September ~~quarter~~30th of 2014 was ~~as follows~~: Division % of Sales Retail Pharmacy 750.800% Total Distribution ~~24.2~~100% Pharma, Health & Beauty 2398.392% Government Pharma 01.908% TOTAL 100.0% GROSS INCOME During the ~~second~~third quarter of 2014, gross income reached $~~1,464~~556.78 million pesos, amount 2070.067% lower than the gross income reached in the ~~second~~third quarter of 2013. This was mainly due ato ~~decrease~~the inFASA ~~sales~~disincorporation inand ~~our~~the ~~distribution~~sales ~~and~~decrease ~~government~~of ~~areas~~the distribution division. OPERATING EXPENSES Operating expenses in the ~~second~~third quarter of 2014 ~~rose~~resulted byin $1,~~542~~185.9 million. This represents a decrease of $606.8 million pesos, or -733.9685%, compared to the same period of the previous year. The decrease was primarily due to the ~~costs~~FASA ofsale ~~opening~~and ~~about~~disincorporation, 84partially ~~new~~offset ~~pharmacies~~by ~~during~~the ~~this~~increase ~~quarter~~of our reserve for uncollectible accounts. As a percentage of total sales, operating expenses ~~represented~~accounted 21for 101.0552% ~~during~~in the ~~second~~third quarter of 2014 ~~compared~~versus toa 1516.4686% ~~during~~for the same period of 2013. OPERATING INCOME Quarterly operating income for ~~2Q2014~~3Q2014 was $-78629.01 million, an amount ~~150~~695.37% lower than the $~~156~~105.17 million reported in ~~2Q2013~~3Q2013. This ~~decrease in operating income~~ was the result of the ~~decline~~effects inof ~~sales due~~ the ~~disincorporation~~factors ofpreviously ~~companies~~mentioned. Operating income margin for the ~~2Q2014~~3Q2014 was 1-53.079%, versus 1.4% in ~~2Q2013~~3Q2013. OPERATING INCOME PLUS DEPRECIATION AND AMORTIZATION (EBITDA) EBITDA for ~~2Q2014~~3Q2014 was $5-605.45 million, a lower amount compared to the $~~242~~200.35 million reported ~~during~~in the ~~second~~third quarter of 2013. EBITDA margin for the third quarter of 2014 was -51.84%. EBITDA margin for the second quarter of 2014 was 0.07%. COMPREHENSIVE COST OF FINANCING (CCF) The ~~Group’s~~Groups CCF reached $~~158~~87.81 million in 3Q2014, 955.1575% lower than the CCF reported during ~~2Q2013~~3Q2013. This decrease was primarily due to the decline and subsequent liquidation of the bank debt. This decrease was primarily due to lower bank debt. NET DEBT ~~The~~Net ~~Company’s net~~ debt at ~~the~~ end of ~~2Q2014~~3T14 ~~was~~has ~~$7,082.8~~been ~~million~~totally ~~pesos~~paid with the funds of the FASA sale. OTHER EXPENSES (INCOME) During the ~~second~~third quarter of the year, other income totaled $~~238~~-1,807.308 million pesos. This was mainly due to ~~extraordinary expenses incurred in a restructuring of~~ the ~~group’s~~FASA ~~subsidiaries.~~sale It is important to mention that the results listed in this line item are derived from activities outside of the company’s normal business operations and, as a result, they are not necessarily recurrentearnings. It is important to mention that the results listed in this line item are derived from activities outside of the ~~company’s~~companys normal business operations and, as a result, they are not necessarily recurrent. TAX PROVISIONS Tax ~~provisions~~losses ~~for~~are ~~the~~expected ~~second~~because ~~quarter~~no ofprovisions ~~2014~~ were ~~$34.5~~made ~~million~~for ~~pesos.~~this ~~While 2Q2013 reported 7~~concept.9 ~~millon.~~ NET INCOME (LOSS) In the ~~second~~third quarter, of 2014, GCS recorded a net ~~loss~~income of $~~509~~ 1,090.891 million with a variation of ~~452~~$ 1,207.51 million compared to the net ~~income~~loss in the same period last year. This ~~change~~variation ~~was~~is mainly due to the ~~decrease~~earnings infor ~~sales~~the ~~previously~~FASA ~~mentioned~~sale, ~~and~~decreased by the ~~cost~~creation of ~~opening~~reserves ~~new~~for ~~pharmacies~~doubtful accounts and sales decrease in the distribution segment. Analysis Coverage: Through the Bolsa Mexicana de Valores program, Independent Analyst, Grupo Casa Saba counts with the coverage of Morningstar. The 265.4 million shares issued by Grupo Casa Saba are listed on the Mexican Stock Exchange under the symbol “SAB”. Grupo Casa Saba was founded in 1892 and is one of the leading distributors of pharmaceutical products, beauty, personal care and consumer goods, general merchandise, publications and other goods in Mexico. With more than 115 years of experience, the Company distributes to the majority of pharmacies, chains, self service and convenience stores, as well as other specialized national chains. With the acquisition of FASA in October of 2010 the company now has retail pharmacy outlets located in Mexico, Chile and Brazil. As a precautionary note to investors, except for the historic information contained herein, certain topics discussed in this document constitute forward looking statements. Such topics imply risks and uncertainties, including the economic conditions in Mexico and those countries in which Grupo Casa Saba operates, directly or indirectly, including the United States of America, Brazil and Chile, as well as variations in the value of the Mexican peso as compared with the currencies of the previously mentioned countries. Contacts: GRUPO CASA SABA IR Communications: Raymundo Barreiro Arpón Jesús Martínez Rojas

GRUPO CASA SABA, S.A.B. DE C.V.
Figures are expressed in thousands of Mexican pesos as of July 2014
Figures are expressed in thousands of Mexican pesos as of september 2014
	Jan-June		Jan-June		Variation		Apr-June		Apr-June		Variation
	jan-sept		Jan-sept		Variation		jul-sept		jul-sept		Variation
Income Statement	2013	% of sales	2014	% of sales	$	%	2013	% of sales	2014	% of sales	$	%
NET SALES	2132,~~860~~495,~~103~~149	100.00%	1517,~~945~~113,~~303~~389	100.00%	5(15,~~914~~381,~~800~~759)	(2747.0634%)	10,~~843~~635,~~357~~046	100.00%	71,~~330~~168,~~375~~087	100.00%	3(9,~~512~~466,~~982~~959)	(3289.4002%)
COST OF SALES	1826,~~139~~875,~~284~~998	82.9871%	1213,~~792~~403,~~667~~982	8078.2332%	5(13,~~346~~472,~~617~~016)	(2950.4813%)	98,~~011~~736,~~019~~715	8382.1015%	5611,~~865,653~~315	8052.0233%	3(8,~~145~~125,~~366~~399)	(3293.9100%)
Gross Profit	35,~~720~~619,~~819~~150	17.0229%	3,~~152~~709,~~636~~407	1921.7768%	~~568~~(1,~~183~~909,743)	(1533.2749%)	1,~~832~~898,~~338~~331	1617.9085%	1556,~~464,722~~771	1947.9867%	~~367~~(1,~~616~~341,560)	(2070.0667%)
OPERATING EXPENSES
Sales Expenses	~~377~~553,~~169~~741	1.~~733~~70%	~~282~~1,~~220~~117,731	16.7753%	94556,~~949~~991	~~(25~~101.1785%)	~~199~~176,~~773~~572	1.8466%	~~120~~835,~~755~~512	171.6553%	79658,~~017~~940	~~(39~~373.5518%)
Administrative Expenses	24,~~919~~536,~~951~~046	13.3696%	23,~~955~~305,~~486~~834	1819.5432%	35(1,~~535~~230,212)	1(27.2212%)	1,~~476~~616,~~407~~095	1315.6220%	1350,~~422,047~~349	1929.4099%	54(1,~~359~~265,747)	(378.6832%)
Operating Expenses	35,~~297~~089,~~120~~787	15.0866%	34,~~237~~423,~~705~~566	2025.3185%	59(666,~~414~~222)	(113.8009%)	1,~~676~~792,~~179~~667	1516.4686%	1,~~542~~185,~~803~~860	21101.0552%	~~133~~(606,~~377~~807)	(733.9685%)
Operating Income	~~423~~529,~~699~~363	1.9463%	(85714,~~069~~158)	(04.5317%)	~~508~~(1,~~769~~243,521)	(~~120~~234.891%)	~~156~~105,~~159~~664	10.4499%	(78629,~~081~~089)	(153.0686%)	~~234~~(734,~~239~~756)	(~~150~~695.0037%)
COMPREHENSIVE COST OF FINANCING
Interest Paid	~~469~~691,~~556~~739	2.1513%	~~346~~449,~~295~~053	2.1762%	~~-123~~(242,~~261~~686)	(2635.2508%)	~~229~~222,~~211~~183	2.1109%	~~177~~102,~~412~~758	28.4280%	~~-51~~(119,~~799~~425)	(2253.6075%)
Interest (Earned)	63(102,~~941~~241)	(0.2931%)	28(65,~~086~~545)	(0.1838%)	3536,~~855~~696	56(35.0789%)	39(38,~~366~~300)	(0.36%)	5(37,~~858~~458)	(03.0821%)	~~45,224~~842	(~~114~~2.8820%)
Exchange Loss (Gain)	46(33,~~185~~286)	(0.2110%)	46(4,~~650~~874)	(0.2915%)	~~464~~8,413	1(25.0127%)	4412,~~337~~899	(0.4112%)	2421,~~445~~756	(01.3386%)	198,~~892~~877	~~(44~~68.8782%)
Monetary Position (gain)	-	0.00%	-	(0.00%)	-	0.00%	-	0.00%	-	0.00%	-	0.00%
Comprehensive Cost of Financing	~~359~~556,~~429~~511	1.6471%	~~271~~358,~~559~~635	12.7010%	87(197,~~871~~577)	(2435.4552%)	~~145~~196,~~508~~782	10.3485%	~~158~~87,~~825~~076	27.1745%	13(109,~~317~~906)	9(55.1575%)
OTHER EXPENSES (INCOME), net	6396,~~786~~066	(0.2930%)	~~172~~(1,~~382~~731,705)	1(10.0812%)	~~108~~(1,~~597~~827,771)	~~170~~(1902.2562%)	6032,~~488~~280	0.5630%	~~238~~(1,~~388~~807,087)	3(154.2570%)	~~177~~(1,~~900~~839,367)	~~294~~(5698.1117%)
NET INCOME BEFORE TAXES	~~484~~(122,914)	(0.0038%)	~~-529~~658,~~011~~912	(3.3285%)	~~529~~781,~~495~~826	(~~109389~~636.3708%)	~~-49~~(123,~~838~~398)	(01.4616%)	~~475~~1,~~294~~090,923	(693.4839%)	~~425~~1,~~456~~214,321	~~853~~(984.6907%)
PROVISIONS FOR:
Income Tax	8278,~~753~~156	0.3824%	75,~~970~~983	0.4844%	6(2,~~783~~173)	(82.2078%)	28(4,~~070~~597)	(0.2604%)	~~30,990~~13	0.4200%	24,~~920~~610	10(100.4029%)
Asset Tax	-	0.00%	-	0.00%	-	0.00%	-	0.00%	-	0.00%	-	0.00%
Deferred Income Tax	-(22,301)	(0.0007%)	(~~20,100~~128)	(0.0900%)	~~128~~22,173	(099.0042%)	19(2,~~972~~201)	(90.3602%)	~~(20,100)~~	(0.1900%)	32,~~601~~201	~~0.05~~(100%)	23,701	(117.92%)
Profit sharing due	-	0.00%	-	0.00%	-	0.00%	-	0.00%	-	0.00%	-	0.00%
Deferred Profit sharing due	-	0.00%	-	0.00%	-	0.00%	-	0.00%	-	0.00%	-	0.00%
Total taxes	6255,~~653~~855	0.2917%	75,~~842~~855	0.4844%	1320,~~189~~000	2135.0581%	7(6,~~970~~799)	(0.0706%)	~~34,592~~13	0.4700%	266,~~621~~812	~~334~~(100.0119%)
Net Income Before Extraordinary Items	~~-62~~(178,~~169~~768)	(0.2855%)	~~604~~583,~~852~~057	(3.7941%)	~~542~~761,~~683~~826	~~872~~(426.9115%)	~~-57~~(116,~~808~~599)	(01.5310%)	~~509~~1,~~885~~090,910	(693.9639%)	~~452~~1,~~078~~207,509	~~782,03~~(1035.61%)
Extraordinary Items (Income)	-	0.00%	-	0.00%	-	0.00%	-	0.00%	-	0.00%	-	0.00%
Net Income	~~-62~~(178,~~169~~768)	(0.2855%)	~~604~~583,~~852~~057	(3.7941%)	~~542~~761,~~683~~826	~~872~~(426.9115%)	~~-57~~(116,~~808~~599)	(01.5310%)	~~509~~1,~~885~~090,910	(693.9639%)	~~452~~1,~~078~~207,509	~~782~~(1035.0361%)
Depreciation and Amortization	~~166~~261,~~966~~821	0.7681%	~~182~~205,~~377~~931	1.1420%	15(55,~~411~~889)	9(21.2335%)	8694,~~153~~855	0.7989%	8323,~~556~~554	12.1402%	2(71,~~597~~300)	(375.0117%)
Operating Income plus Depreciation and Amortization	~~590~~791,~~665~~184	2.0743%	97(508,~~308~~227)	0(2.6197%)	~~493~~(1,~~358~~299,411)	(~~83,53~~164.24%)	~~242~~200,~~312~~519	21.2389%	5(605,~~476~~585)	0(51.0784%)	~~236~~(806,~~836~~053)	~~(97~~401.7498%)
Net Income corresponding to Minority Interest	46,~~672~~219	-	-3(1,~~037~~970)	(0.0201%)	7(8,~~710~~189)	(~~165~~131.0168%)	21,~~840~~547	-	-31,~~639~~067	0.0509%	~~6,478~~(479)	(~~228~~30.1597%)

	QUARTER CURRENT YEAR	CLOSE PRIOR YEAR
	AMOUNT	AMOUNT
TOTAL ASSETS	257,~~963~~887,~~098~~673	28,513,587
CURRENT ASSETS	145,~~945~~629,~~805~~279	17,435,810
CASH AND CASH EQUIVALENTS	~~838~~398,~~932~~649	1,135,536
CLIENTS (NET)	51,~~430~~929,~~585~~343	6,664,165
CLIENTS	73,~~060~~795,~~183~~007	8,257,575
ALLOWANCE FOR DOUBTFUL ACCOUNTS	-11865,~~629,598~~664	-1,593,410
OTHER ACCOUNTS RECEIVABLES (NET)	31,~~445~~929,~~091~~409	2,404,310
INVENTORIES	51,~~220~~361,~~352~~661	7,219,119
OTHER CURRENT ASSETS	10,~~845~~217	12,680
LONG TERM	~~36,139~~	33,052
INVESTMENTS IN SHARES OF SUBSIDIARIES AND
ASSOCIATED COMPANIES	~~36,139~~	33,052
PROPERTY MACHINARY AND EQUIPMENT NET	31,~~101~~797,~~192~~381	3,115,617
PROPERTY	21,~~353~~586,~~430~~054	2,249,221
MACHINERY AND EQUIPMENT	2478,~~499,982~~520	2,644,~~098~~048
OTHER EQUIPMENT	1465,~~413,524~~343	1,764,214
ACCUMULATED DEPRECIATION	-3732,~~165,744~~536	-3,554,540
CONSTRUCTION IN PROGRESS	0	12,674
INTANGIBLE ASSETS (NET)	6193,~~558,611~~809	6,567,239
GOODWILL	2156,~~421,035~~263	2,462,132
BRANDS	~~2,737,991~~	2,677,690
RIGHTS AND LICENSING	127,~~389,484~~425	1,412,252
OTHER INTANGIBLE ASSETS	10,~~101~~121	15,165
OTHER NON CURRENT ASSETS	1267,~~321,351~~204	1,361,869
ADVANCE PAYMENTS	~~116~~111,~~761~~392	28,623
DEFERRED CHARGES (NET)
OTHERS	1155,~~204,590~~812	1,333,246
TOTAL LIABILITIES	226,~~022~~490,~~969~~482	23,928,776
CURRENT LIABILITIES	135,~~815~~857,~~552~~145	15,837,330
BANK CREDITS	~~1,822,161~~	1,683,123
SUPPLIERS	115,~~318~~653,~~236~~816	13,411,416
TAXES PAYABLE	~~675~~203,~~155~~329	742,791
OTHER CURRENT LIABILITIES	1843,~~729,080~~758	1,123,201
EMPLOYEE BENEFITS	317,437	280,710
OTHER CURRENT LIABILITIES	1526,~~411,643~~321	842,491
NON CURRENT LIABILITIES	~~6,942,264~~	7,373,937
BANK CREDITS	~~6,942,264~~	7,373,937
OTHER LIABILITIES	-~~463~~210,~~927~~421	-405,692
SHAREHOLDERS' EQUITY	31,~~940~~397,~~129~~191	4,548,811
CONTRIBUTED CAPITAL	2,593,872	2,593,972
CAPITAL STOCK PAID (NOMINAL)	767,902	767,902
CAPITAL STOCK PAID UPDATE	956,093	956,093
PREMIUM ON STOCK SOLD	869,877	869,877
CAPITAL INCREASE (DECREASE)	-1,~~346~~196,~~257~~681	1,990,939
ACCUMULATED PROFIT AND LEGAL RESERVE	~~888~~-2,~~909~~841,938	1,415,907
RESERVE FOR STOCK REPURCHASE	1,062,200	1,062,200
PROFIT	~~-604~~583,~~852~~057	-487,168

Filing Compare · GRUPO CASA SABA, S.A.B. DE C.V.